Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / Pacira BioSciences, Inc.

M&Acompleted an acquisition (SEC 8-K)17 Nov 2026

Pacira BioSciences, Inc.

17 Nov 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
17 Nov 2026
Ticker
PCRX
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2834
Items
1.01, 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
Summary
As previously disclosed, pursuant to the Merger Agreement, on October 30, 2026, Purchaser commenced a tender offer to acquire all of the outstanding shares of common stock of the Company, $0.001 par value per share (the "Shares"), at an offer price of $36.50 per Share in cash, net of applicable withholding taxes and wi
Location
Brisbane, CA
State
California
Country
United States
SEC CIK
1396814
Reference
0001140361-26-044354
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at Pacira BioSciences, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.